Onepot AI, a pioneer in automated chemical synthesis, secured $13 million in fresh funding to accelerate drug development and expand its San Francisco laboratory operations. The capital injection allows the startup to establish a second facility, scale its proprietary compound discovery engine, and grow its technical team to meet increasing market demand.
Scaling Infrastructure and San Francisco Expansion
The new investment facilitates the construction of a second laboratory in San Francisco, a move designed to increase the firm’s throughput and accommodate a larger client base. By enhancing its discovery engine, Onepot AI positions itself as a high-tech alternative to traditional industry giants such as WuXi AppTec and Enamine.
Doubling the Speed of Pharmaceutical Innovation
Founders Boiko and Tyrin aim to slash drug development timelines by at least 50%. Their methodology leverages “weird” chemistry—molecular pathways and structures previously dismissed by the scientific community as inaccessible or off-limits. This focus on unconventional chemical synthesis seeks to fundamentally alter how researchers approach complex drug design.
Expanding the Design Space for Future Therapeutics
The company’s vision extends beyond mere efficiency to the creation of entirely new classes of materials and medicines. According to Boiko, the platform unlocks a vast, previously unreachable territory in molecular architecture. “You’re not just speeding up drug discovery, you’re expanding the design space for what drugs and materials can be,” Boiko stated. He emphasized that critical, undiscovered treatments likely exist within this expanded space, currently awaiting identification through advanced discovery tools.
